AKT1 and Hyperglycemia: PI3K/AKT pathway inhibition disrupts these processes, leading to reduced glucose uptake, increased gluconeogenesis, and impaired insulin signaling, making hyperglycemia a common side effect of PI3K/AKT inhibitors (Fig. 3)15,51–54.